RESPIROLOGY is a prestigious academic journal that focuses on the field of Pulmonary and Respiratory Medicine, publishing high-quality research and comprehensive reviews that contribute significantly to the understanding and management of respiratory health. As a distinguished publication of WILEY, it has established a strong presence in the academic world with an impressive impact factor and ranked in the Q1 category, recognized for its influence and innovation in the field. RESPIROLOGY is committed to disseminating cutting-edge research from 1996 through 2024, appearing regularly in SCOPUS with a rank of #14 out of 155, placing it in the rarefied 91st percentile among its peers. The journal invites contributions from researchers, professionals, and students, fostering a collaborative space for advancing knowledge in pulmonary medicine. Although it does not offer open access, its readership spans globally, indicating the high regard in which it is held within the scientific community.

Therapeutic Advances in Respiratory Disease is a prestigious open-access journal published by SAGE Publications Ltd, based in the United Kingdom. Since its inception in 2007, it has established itself as a leading platform for the dissemination of cutting-edge research in the fields of pulmonary and respiratory medicine and pharmacology. With an impressive impact factor and ranking—showing it is in the Q1 quartile in both Pharmacology (medical) and Pulmonary and Respiratory Medicine as of 2023—the journal's commitment to high-quality research is evident. In 2023, it ranks #32 out of 155 in Pulmonary and Respiratory Medicine and #57 out of 272 in Medical Pharmacology, positioning it in the 79th percentile across these disciplines. Open access since 2018, the journal ensures that its valuable content is readily accessible to a global audience of researchers, healthcare professionals, and students, facilitating the rapid exchange of knowledge that is crucial in the ever-evolving landscape of respiratory health. The journal's objectives include advancing understanding of respiratory diseases through innovative research and promoting the development of therapeutic strategies that improve patient outcomes, making it an essential resource for those dedicated to respiratory medicine.

LUNG is a prestigious academic journal that has been a cornerstone in the field of Pulmonary and Respiratory Medicine since its inception in 1959. Published by SPRINGER, the journal holds an impressive Q1 ranking in its category for 2023, reflecting its commitment to disseminating high-quality research and advancing clinical practices in respiratory health. With a Scopus rank of 24 out of 155 in its field, representing the top 16% of journals, LUNG continues to serve as a vital platform for researchers, clinicians, and students who are dedicated to addressing the complexities of lung diseases. Although currently not an open-access journal, LUNG offers valuable insights and significant contributions to the understanding of respiratory conditions, ensuring that its readership stays at the forefront of medical advancements. Researchers and professionals are encouraged to submit their work and engage with a thriving academic community that is passionate about improving patient outcomes in pulmonary health.

THORAX is a premier academic journal dedicated to advancing knowledge in the field of Pulmonary and Respiratory Medicine. Published by the esteemed BMJ Publishing Group in the United Kingdom, this journal has been a pivotal resource for researchers and clinicians since its inception in 1946. With a remarkable ranking of #6 out of 155 in its category, THORAX holds a prestigious position within the top 4% of its field, as indicated by its 2023 Q1 quartile classification and a strong Scopus ranking. The journal focuses on publishing high-quality research, reviews, and clinical studies that are essential for understanding respiratory diseases and their management. Although it is not an open-access journal, THORAX provides vital contributions to the academic community, fostering dialogue and innovation in pulmonary medicine. As it approaches its converged years, concluding in 2024, researchers, professionals, and students are encouraged to explore its rich repository of knowledge, while engaging with the most current advancements in the field.

CHEST is a premier journal published by Elsevier, focusing on the vital fields of cardiology, critical care, and pulmonary medicine. Established in 1970, this esteemed journal has continually provided authoritative research, reviews, and clinical studies, catering to a global audience of healthcare professionals, researchers, and students. With an impressive impact factor, CHEST ranks in the top quartile (Q1) across its core categories according to the latest Scopus metrics, securing its position as a leading resource within cardiology (Rank #16), pulmonary (Rank #9), and critical care (Rank #8). Published quarterly, it offers a wealth of knowledge essential for advancing understanding and improving patient outcomes in these critical areas of healthcare. Researchers and practitioners are encouraged to submit their work, contributing to the ongoing discourse that shapes innovative practices and policies in respiratory and cardiovascular health.

Zeitschrift für Pneumologie is a pivotal journal in the field of Pulmonary and Respiratory Medicine, published by Springer Heidelberg, a renowned name in academic publishing. With its ISSN number 2731-7404, it serves as a vital platform for disseminating innovative research and clinical studies relevant to lung health and diseases. This German-based journal aims to bridge the gap between research and practice, encouraging submissions that advance knowledge in respiratory medicine, including pathophysiology, treatment modalities, and patient care strategies. Although currently categorized in the Q4 quartile within its field, its commitment to quality research and emerging insights positions it as an essential resource for researchers, healthcare professionals, and students dedicated to improving respiratory health. The journal operates within the convergence period from 2022 to 2024, promising a dynamic evolution of its content. With limited open access availability, it encourages readership and contribution from its audience, fostering a collaborative academic environment.

The Egyptian Journal of Chest Diseases and Tuberculosis is a premier Open Access journal published by Wolters Kluwer Medknow Publications, focusing on the latest advancements in the fields of respiratory diseases, pulmonary medicine, and tuberculosis management. With an ISSN of 0422-7638 and an E-ISSN of 2090-9950, this journal aims to disseminate high-quality research, reviews, and clinical insights that advance the understanding and treatment of chest diseases. Since its transition to Open Access in 2018, the journal has garnered increased visibility, enabling researchers across the globe to contribute and access valuable content without barriers. Situated in India, the journal is dedicated to bridging the gap between clinical practice and research, emphasizing the significance of innovative therapeutic strategies and public health approaches in combating respiratory illnesses. We invite researchers, healthcare professionals, and students to engage with our publications as we continue to foster knowledge and foster collaboration within the global medical community.

The EUROPEAN RESPIRATORY JOURNAL, published by EUROPEAN RESPIRATORY SOC JOURNALS LTD, is at the forefront of advancing knowledge in the fields of pulmonary and respiratory medicine. With its ISSN 0903-1936 and E-ISSN 1399-3003, this esteemed journal has established itself as a leading platform since its inception in 1988, currently converging towards 2024. Ranked in the Q1 category for both Medicine (miscellaneous) and Pulmonary and Respiratory Medicine in 2023, it stands as the 3rd of 155 journals in its field, reflecting an impressive 98th percentile Scopus ranking. The journal boasts a rigorous selection of peer-reviewed articles that encompass innovative research, clinical studies, and reviews, thereby enhancing the understanding and treatment of respiratory diseases. Although it does not currently offer an Open Access option, the journal remains crucial for researchers, clinicians, and healthcare professionals committed to improving respiratory health across Europe and beyond. Join a community dedicated to groundbreaking research and advancements in respiratory medicine.

BMJ Open Respiratory Research is a prestigious open access journal published by the BMJ Publishing Group, dedicated to advancing the field of pulmonary and respiratory medicine. Since its inception in 2014, the journal has provided a vital platform for the dissemination of innovative research and clinical findings, boasting an impressive Q1 ranking in its category as of 2023. With a Scopus rank of #35 out of 155 in Pulmonary and Respiratory Medicine, BMJ Open Respiratory Research is recognized for its high-quality content, engaging a global audience of researchers, healthcare professionals, and students. The journal embraces an open access model, ensuring that groundbreaking research is readily available to the community and stakeholders, thereby accelerating knowledge exchange and improving patient care. By focusing on diverse aspects of respiratory health, this journal plays a crucial role in shaping the future of respiratory research and practice.

Tuberculosis and Respiratory Diseases is a leading open-access journal published by THE KOREAN ACADEMY OF TUBERCULOSIS & RESPIRATORY DISEASES, dedicated to disseminating knowledge in the fields of infectious diseases and pulmonary medicine. Since its inception in 1980, the journal has undergone significant growth, currently recognized in the elite Q2 category for both Infectious Diseases and Pulmonary and Respiratory Medicine as of 2023. With an impact factor reflecting its esteemed position—ranked 52nd in its category—it serves as a vital resource for researchers and healthcare professionals seeking cutting-edge insights, studies, and advancements in the management and treatment of respiratory diseases, particularly tuberculosis. The journal is committed to providing open access to its content since 2013, ensuring that critical research is available to scholars worldwide, fostering collaboration and innovation in the global fight against respiratory illnesses.